Power3 Medical Products, Inc. (OTCBB:PWRM.OB)
Power3 Medical has recently announced that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.
Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.
PTS Inc. (OTCPK:PTSH) entered into a Share Exchange Agreement pursuant to which PTSH will acquire 70% of ThinLine Technology Group at the closing. Closing shall occur as soon as PTSH receives satisfactory audited financials from ThinLine, but not later than December 31, 2010.
ThinLine Technology Group manages, markets and maintains the IT and VOIP infrastructure for small and medium business (SMB market) and provides Private Cable Operators, private label billing and call center support. At present, the company services over 21,000 clients on behalf of Private Cable Operators over 400 apartment properties across the United States.
For more information about this company please visit www.ptspi.com
BioDelivery Sciences International, Inc. (Nasdaq:BDSI) reported a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) which took place on September 14, 2010. At that meeting, agreement was reached on the BEMA Buprenorphine development plan for the treatment of chronic pain. As a result, the Phase 3 clinical program evaluating the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain will be initiated this quarter.
BioDelivery Sciences International is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.
BioFuel Energy Corp. (Nasdaq:BIOF) declared that it will be releasing its third quarter 2010 earnings on Wednesday, November 10, 2010, after the market closes.
BioFuel Energy plans to host a conference call on Thursday, November 11, 2010, beginning at 1:00 p.m. (EST) to discuss the results. To participate, please dial (800) 944-8766 begin_of_the_skype_highlighting (800) 944-8766 end_of_the_skype_highlighting. The participant code for the call is 13119. This call will be available for phone playback for 30 days by dialing (866) 281-6782 begin_of_the_skype_highlighting (866) 281-6782 end_of_the_skype_highlighting. The access code for the replay is 153871.
BioFuel Energy currently has two 115 million gallons a year ethanol plants operating in the Midwestern corn belt. BioFuel Energy’s goal is to become a leading ethanol producer in the United States by acquiring, developing, owning and operating ethanol production facilities.
Biogen Idec (Nasdaq:BIIB) and Cardiokine, Inc. recently announced that they have agreed to dissolve their collaboration on lixivaptan. The termination of the collaboration, which began in 2007, triggers the return of all rights to lixivaptan to Cardiokine.
The agreement is consistent with Biogen Idec’s broader strategic decision, which was announced earlier today, to narrow its research and development (R&D) focus and terminate its efforts in cardiovascular medicine and was reached before completion of the Phase 3 development program for lixivaptan.
Biogen Idec uses cutting edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders.
Sign-Up For Free Stock Alerts At crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM). Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for PTS Inc. (OTCPK:PTSH).
Power3 Medical Products, Inc. (OTCBB:PWRM.OB)